Published in JAMA on November 19, 2008
Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med (2011) 19.42
Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology (2012) 11.91
Adverse effects of anticancer agents that target the VEGF pathway. Nat Rev Clin Oncol (2009) 3.43
Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. J Clin Oncol (2012) 2.61
The safety and side effects of monoclonal antibodies. Nat Rev Drug Discov (2010) 2.23
Assessing risk of venous thromboembolism in the patient with cancer. J Clin Oncol (2009) 2.22
Regulation of nitric oxide signalling by thrombospondin 1: implications for anti-angiogenic therapies. Nat Rev Cancer (2009) 1.95
Epidemiology and pathophysiology of cancer-associated thrombosis. Br J Cancer (2010) 1.93
Key roles for the lipid signaling enzyme phospholipase d1 in the tumor microenvironment during tumor angiogenesis and metastasis. Sci Signal (2012) 1.86
Molecular basis for the regulation of angiogenesis by thrombospondin-1 and -2. Cold Spring Harb Perspect Med (2012) 1.68
Recurrent glioblastoma treated with bevacizumab: contrast-enhanced T1-weighted subtraction maps improve tumor delineation and aid prediction of survival in a multicenter clinical trial. Radiology (2013) 1.55
Bevacizumab-induced serious side-effects: a review of the French pharmacovigilance database. Eur J Clin Pharmacol (2012) 1.52
von Willebrand factor fibers promote cancer-associated platelet aggregation in malignant melanoma of mice and humans. Blood (2015) 1.46
Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma. J Clin Oncol (2010) 1.37
Cancer, clots and consensus: new understanding of an old problem. J Clin Oncol (2009) 1.35
Bevacizumab toxicities and their management in ovarian cancer. Gynecol Oncol (2010) 1.27
Anti-vascular endothelial growth factor therapies and cardiovascular toxicity: what are the important clinical markers to target? Oncologist (2010) 1.27
Cancer-associated thrombosis: an overview. Clin Med Insights Oncol (2014) 1.23
Venous thromboembolism prophylaxis and treatment in cancer: a consensus statement of major guidelines panels and call to action. J Clin Oncol (2009) 1.21
Anti-VEGF therapies in the clinic. Cold Spring Harb Perspect Med (2012) 1.20
Antiangiogenic therapy for advanced renal cell carcinoma: management of treatment-related toxicities. Invest New Drugs (2012) 1.13
New insights into cancer-associated thrombosis. Arterioscler Thromb Vasc Biol (2009) 1.11
Venous thromboembolism in the patient with cancer: focus on burden of disease and benefits of thromboprophylaxis. Cancer (2010) 1.10
Vascular endothelial growth factor as an anti-angiogenic target for cancer therapy. Curr Drug Targets (2010) 1.07
Cardiovascular toxicities: clues to optimal administration of vascular endothelial growth factor signaling pathway inhibitors. Target Oncol (2009) 1.07
Five-Year Outcomes with Anti-Vascular Endothelial Growth Factor Treatment of Neovascular Age-Related Macular Degeneration: The Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology (2016) 1.04
Bevacizumab and Breast Cancer: A Meta-Analysis of First-Line Phase III Studies and a Critical Reappraisal of Available Evidence. J Oncol (2012) 1.03
Management of antiangiogenic therapy-induced hypertension. Hypertension (2012) 1.02
Cancer-related coagulopathy (Trousseau's syndrome): review of the literature and experience of a single center of internal medicine. Clin Exp Med (2013) 1.01
Effects of bevacizumab plus irinotecan on response and survival in patients with recurrent malignant glioma: a systematic review and survival-gain analysis. BMC Cancer (2010) 1.01
Adverse events to monoclonal antibodies used for cancer therapy: Focus on hypersensitivity responses. Oncoimmunology (2013) 1.01
The evolving role of monoclonal antibodies in colorectal cancer: early presumptions and impact on clinical trial development. Oncologist (2010) 1.00
Toxic effects and their management: daily clinical challenges in the treatment of colorectal cancer. Nat Rev Clin Oncol (2009) 1.00
Adverse events with intravitreal injection of vascular endothelial growth factor inhibitors: nested case-control study. BMJ (2012) 1.00
Magnitude of benefit of the addition of bevacizumab to first-line chemotherapy for metastatic colorectal cancer: meta-analysis of randomized clinical trials. J Exp Clin Cancer Res (2010) 1.00
An updated meta-analysis of fatal adverse events caused by bevacizumab therapy in cancer patients. PLoS One (2014) 0.99
Phase II study of gemcitabine, carboplatin, and bevacizumab in patients with advanced unresectable or metastatic urothelial cancer. J Clin Oncol (2013) 0.97
Safety of bevacizumab in patients with advanced cancer: a meta-analysis of randomized controlled trials. Oncologist (2010) 0.96
Noncardiac vascular toxicities of vascular endothelial growth factor inhibitors in advanced cancer: a review. Oncologist (2011) 0.95
Phase II and coagulation cascade biomarker study of bevacizumab with or without docetaxel in patients with previously treated metastatic pancreatic adenocarcinoma. Am J Clin Oncol (2011) 0.94
Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer. BMC Cancer (2011) 0.94
Cardiovascular complications associated with novel angiogenesis inhibitors: emerging evidence and evolving perspectives. Trends Cardiovasc Med (2013) 0.94
Medical management of brain tumors and the sequelae of treatment. Neuro Oncol (2014) 0.94
Risk of site-specific cancer in incident venous thromboembolism: a population-based study. Thromb Res (2014) 0.94
Venous thromboembolic disease. J Natl Compr Canc Netw (2011) 0.93
Management of treatment-associated toxicites of anti-angiogenic therapy in patients with brain tumors. Neuro Oncol (2012) 0.93
Treatment-related mortality with aflibercept in cancer patients: a meta-analysis. Eur J Clin Pharmacol (2014) 0.93
Bevacizumab-based therapies in the first-line treatment of metastatic colorectal cancer. Oncologist (2012) 0.92
Venous thromboembolism in malignant gliomas. J Thromb Haemost (2009) 0.92
A post hoc analysis of dalteparin versus oral anticoagulant (VKA) therapy for the prevention of recurrent venous thromboembolism (rVTE) in patients with cancer and renal impairment. J Thromb Thrombolysis (2016) 0.91
Cellular and physiological roles for phospholipase D1 in cancer. J Biol Chem (2014) 0.91
Kinase inhibitors and monoclonal antibodies in oncology: clinical implications. Nat Rev Clin Oncol (2015) 0.90
Thromboprophylaxis with low-molecular-weight heparin in medical patients with cancer. Cancer (2009) 0.90
Consolidation paclitaxel is more cost-effective than bevacizumab following upfront treatment of advanced epithelial ovarian cancer. Gynecol Oncol (2011) 0.89
Effect of angiogenesis inhibitor bevacizumab on survival in patients with cancer: a meta-analysis of the published literature. PLoS One (2012) 0.89
Ziv-aflibercept in metastatic colorectal cancer. Biologics (2013) 0.88
Thrombosis and cancer. Nat Rev Clin Oncol (2012) 0.88
Review of systemic therapies for locally advanced and metastatic rectal cancer. J Gastrointest Oncol (2015) 0.88
Inferior vena cava filters for primary prophylaxis: when are they indicated? Semin Intervent Radiol (2012) 0.88
Therapeutic antibodies against cancer. Hematol Oncol Clin North Am (2012) 0.87
The potential benefits of low-molecular-weight heparins in cancer patients. J Hematol Oncol (2010) 0.87
Health economic aspects of breast cancer treatment: the compulsory health insurances' view. Breast Care (Basel) (2013) 0.86
Antiangiogenic therapies in early-stage breast cancer. Clin Breast Cancer (2010) 0.86
Thromboembolic disease in patients with high-grade glioma. Neuro Oncol (2012) 0.85
Safety of bevacizumab in patients with malignant gliomas: a systematic review. Neurol Sci (2013) 0.84
Bevacizumab in high-grade gliomas: a review of its uses, toxicity assessment, and future treatment challenges. Onco Targets Ther (2013) 0.84
Cancer therapy and cardiovascular risk: focus on bevacizumab. Cancer Manag Res (2015) 0.84
Risks of proteinuria associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a systematic review and meta-analysis. PLoS One (2014) 0.83
Bevacizumab. Oncologist (2010) 0.83
Risk of venous thromboembolism with bevacizumab in cancer patients. JAMA (2009) 0.83
Synthesis and antiangiogenic activity of N-alkylated levamisole derivatives. PLoS One (2012) 0.83
Value of bevacizumab in treatment of colorectal cancer: A meta-analysis. World J Gastroenterol (2015) 0.83
CATCH: a randomised clinical trial comparing long-term tinzaparin versus warfarin for treatment of acute venous thromboembolism in cancer patients. BMC Cancer (2013) 0.82
First-in-human phase I study of PRS-050 (Angiocal), an Anticalin targeting and antagonizing VEGF-A, in patients with advanced solid tumors. PLoS One (2013) 0.82
Pulmonary embolism due to internal jugular vein thrombosis in a patient with non-small cell lung cancer receiving bevacizumab. Int J Clin Oncol (2010) 0.82
Anti-angiogenic therapy in high-grade glioma (treatment and toxicity). Curr Treat Options Neurol (2013) 0.81
CalDAG-GEFI deficiency protects mice from FcγRIIa-mediated thrombotic thrombocytopenia induced by CD40L and β2GPI immune complexes. J Thromb Haemost (2014) 0.81
Cardiovascular safety of VEGF-targeting therapies: current evidence and handling strategies. Oncologist (2010) 0.81
Bevacizumab for glioblastoma. Ther Clin Risk Manag (2015) 0.81
Multimodality multiparametric imaging of early tumor response to a novel antiangiogenic therapy based on anticalins. PLoS One (2014) 0.81
Incidence and management of ZIv-aflibercept related toxicities in colorectal cancer. World J Clin Oncol (2014) 0.81
Congestive heart failure risk in cancer patients treated with vascular endothelial growth factor tyrosine kinase inhibitors: a systematic review and meta-analysis of 36 clinical trials. Br J Clin Pharmacol (2014) 0.80
An Association between Bevacizumab and Recurrent Posterior Reversible Encephalopathy Syndrome in a Patient Presenting with Deep Vein Thrombosis: A Case Report and Review of the Literature. Case Rep Oncol Med (2012) 0.80
Use of Vacuum-assisted closure in management of open abdominal wound with multiple enterocutaneous fistulae during chemotherapy: A case report. Int J Surg Case Rep (2015) 0.80
Practical management of bevacizumab-related toxicities in glioblastoma. Oncologist (2015) 0.80
Bevacizumab in combination with FOLFIRI chemotherapy in patients with metastatic colorectal cancer: an assessment of safety and efficacy in the province of Newfoundland and Labrador. Curr Oncol (2010) 0.80
Adverse events of monoclonal antibodies used for cancer therapy. Biomed Res Int (2015) 0.80
Cancer and coagulation. Am J Hematol (2012) 0.80
Guidelines for treatment and prevention of venous thromboembolism among patients with cancer. Thromb Res (2014) 0.80
Combination therapy for scalp angiosarcoma using bevacizumab and chemotherapy: a case report and review of literature. Chin J Cancer Res (2013) 0.79
Anti-Vascular endothelial growth factor therapy impairs endothelial function of retinal microcirculation in colon cancer patients - an observational study. Exp Transl Stroke Med (2013) 0.79
Cardiovascular Toxicity of Molecular Targeted Therapy in Cancer Patients: A Double-Edged Sword. Zhonghua Minguo Xin Zang Xue Hui Za Zhi (2013) 0.79
Venous thromboembolism in the cancer population: pathology, risk, and prevention. J Adv Pract Oncol (2012) 0.79
Risk of venous and arterial thromboembolic events in cancer patients treated with gemcitabine: a systematic review and meta-analysis. Br J Clin Pharmacol (2013) 0.79
What is the Best Treatment for a Cancer Patient with Thrombosis? Clin Med Insights Oncol (2014) 0.78
Effect of intravitreal anti-vascular endothelial growth factor therapy on the risk of arterial thromboembolic events: a meta-analysis. PLoS One (2012) 0.78
Cardiotoxicity of molecularly targeted agents. Curr Cardiol Rev (2011) 0.78
Phosphatase inhibitors with anti-angiogenic effect in vitro. APMIS (2010) 0.78
A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med (2003) 6.99
Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis. JAMA (2011) 6.14
Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis (2007) 3.47
Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis. Lancet Oncol (2009) 2.87
Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis. Lancet Oncol (2008) 2.63
Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. Oncologist (2008) 2.22
The role of human metapneumovirus in upper respiratory tract infections in children: a 20-year experience. J Infect Dis (2005) 2.02
The kinetic stability of MHC class II:peptide complexes is a key parameter that dictates immunodominance. Immunity (2005) 1.88
Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342. J Clin Oncol (2004) 1.83
Phosphorylation-dependent paxillin-ERK association mediates hepatocyte growth factor-stimulated epithelial morphogenesis. Mol Cell (2003) 1.83
Quality of life outcomes in 599 cancer and non-cancer patients with colostomies. J Surg Res (2006) 1.83
Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis. Acta Oncol (2009) 1.82
Risk of skin rash associated with erlotinib in cancer patients: a meta-analysis. J Support Oncol (2010) 1.50
Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis. Am J Hypertens (2010) 1.50
Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials. Acta Oncol (2010) 1.48
Revision and psychometric testing of the City of Hope Quality of Life-Ostomy Questionnaire. Qual Life Res (2004) 1.46
Pruritus in patients treated with targeted cancer therapies: systematic review and meta-analysis. J Am Acad Dermatol (2013) 1.45
Single amino acid changes in the Nipah and Hendra virus attachment glycoproteins distinguish ephrinB2 from ephrinB3 usage. J Virol (2007) 1.44
Bevacizumab increases risk for severe proteinuria in cancer patients. J Am Soc Nephrol (2010) 1.44
Risk of hand-foot skin reaction with sorafenib: a systematic review and meta-analysis. Acta Oncol (2008) 1.39
Risk of hand-foot skin reaction with the multitargeted kinase inhibitor sunitinib in patients with renal cell and non-renal cell carcinoma: a meta-analysis. Clin Genitourin Cancer (2009) 1.34
Increased risk of serious hemorrhage with bevacizumab in cancer patients: a meta-analysis. Oncology (2010) 1.31
Nonnatural protein-protein interaction-pair design by key residues grafting. Proc Natl Acad Sci U S A (2007) 1.30
Community-wide evaluation of methods for predicting the effect of mutations on protein-protein interactions. Proteins (2013) 1.20
Efficacy of etanercept in preventing relapse of uveitis controlled by methotrexate. Arch Ophthalmol (2003) 1.16
Noninvasive identification of human central sulcus: a comparison of gyral morphology, functional MRI, dipole localization, and direct cortical mapping. Neuroimage (2003) 1.16
Indications and use of palliative surgery-results of Society of Surgical Oncology survey. Ann Surg Oncol (2002) 1.14
Positron emission tomography scanning poorly predicts response to preoperative chemotherapy in non-small cell lung cancer. Ann Thorac Surg (2004) 1.10
Case 7-2006: a man with altered mental status and acute renal failure. N Engl J Med (2006) 1.09
Cysteines in the stalk of the nipah virus G glycoprotein are located in a distinct subdomain critical for fusion activation. J Virol (2012) 1.08
Activation of nuclear factor kappaB in radioresistance of TP53-inactive human keratinocytes. Cancer Res (2002) 1.08
Complications in resident-performed phacoemulsification cataract surgery at New Jersey Medical School. Br J Ophthalmol (2007) 1.06
Histone deacetylase inhibition activates transcription factor Nrf2 and protects against cerebral ischemic damage. Free Radic Biol Med (2011) 1.05
Ocular manifestations and concepts of systemic vasculitides. Surv Ophthalmol (2004) 1.01
The risk of hand foot skin reaction to pazopanib, a novel multikinase inhibitor: a systematic review of literature and meta-analysis. Invest New Drugs (2011) 1.00
Phase I trial of intraperitoneal docetaxel in the treatment of advanced malignancies primarily confined to the peritoneal cavity: dose-limiting toxicity and pharmacokinetics. Clin Cancer Res (2003) 1.00
Normal versus high tension glaucoma: a comparison of functional and structural defects. J Glaucoma (2010) 0.99
Refined Qing Kai Ling, traditional Chinese medicinal preparation, reduces ischemic stroke-induced infarct size and neurological deficits and increases expression of endothelial nitric oxide synthase. Biol Pharm Bull (2008) 0.99
Elevated levels of interleukin 6 in the vitreous fluid of patients with pars planitis and posterior uveitis: the Massachusetts eye & ear experience and review of previous studies. Ocul Immunol Inflamm (2004) 0.99
Simvastatin attenuates stroke-induced splenic atrophy and lung susceptibility to spontaneous bacterial infection in mice. Stroke (2013) 0.99
Risk of cardiac dysfunction with trastuzumab in breast cancer patients: a meta-analysis. Cancer Treat Rev (2010) 0.98
Possible lowest-energy geometry of silicon clusters Si21 and Si25. J Am Chem Soc (2003) 0.97
Impact of sentinel node status and other risk factors on the clinical outcome of head and neck melanoma patients. Arch Otolaryngol Head Neck Surg (2006) 0.97
Sunitinib in metastatic renal cell carcinoma: recommendations for management of noncardiovascular toxicities. Oncologist (2011) 0.97
Factors predictive of the status of sentinel lymph nodes in melanoma patients from a large multicenter database. Ann Surg Oncol (2011) 0.97
Risk of hand-foot skin reaction with the novel multikinase inhibitor regorafenib: a meta-analysis. Invest New Drugs (2013) 0.96
Risk of rash in cancer patients treated with vandetanib: systematic review and meta-analysis. J Clin Endocrinol Metab (2012) 0.96
Treatment of ocular inflammatory disorders with daclizumab. Ophthalmology (2003) 0.96
A mechanistic study of tumor-targeted corrole toxicity. Mol Pharm (2011) 0.96
Pre-clinical and clinical evaluation of estramustine, docetaxel and thalidomide combination in androgen-independent prostate cancer. BJU Int (2007) 0.95
Histone deacetylase isoforms regulate innate immune responses by deacetylating mitogen-activated protein kinase phosphatase-1. J Leukoc Biol (2013) 0.94
Risk of high-grade skin rash in cancer patients treated with cetuximab--an antibody against epidermal growth factor receptor: systemic review and meta-analysis. Oncology (2009) 0.94
Preoperative taxane-based chemotherapy and celecoxib for carcinoma of the esophagus and gastroesophageal junction: results of a phase 2 trial. J Thorac Oncol (2011) 0.91
Chemotherapy targeting by DNA capture in viral protein particles. Nanomedicine (Lond) (2012) 0.90
Risk of liver toxicity with the angiogenesis inhibitor pazopanib in cancer patients. Acta Oncol (2013) 0.90
Heat shock-mediated thermoprotection of larval locomotion compromised by ubiquitous overexpression of Hsp70 in Drosophila melanogaster. J Neurophysiol (2005) 0.89
Mutational spectra of p53 in geographically localized esophageal squamous cell carcinoma groups in China. Cancer (2004) 0.89
Rash to the mTOR inhibitor everolimus: systematic review and meta-analysis. Am J Clin Oncol (2014) 0.89
Rash with the multitargeted kinase inhibitors nilotinib and dasatinib: meta-analysis and clinical characterization. Eur J Haematol (2013) 0.88
Increased risk of high-grade dermatologic toxicities with radiation plus epidermal growth factor receptor inhibitor therapy. Cancer (2009) 0.88
The risk of hand-foot skin reaction to axitinib, a novel VEGF inhibitor: a systematic review of literature and meta-analysis. Invest New Drugs (2013) 0.88
Surgical resection for residual N2 disease after induction chemotherapy. Ann Thorac Surg (2005) 0.87
The efficacy of temozolomide for recurrent glioblastoma multiforme. Eur J Neurol (2012) 0.86
Multimodality imaging in vivo for preclinical assessment of tumor-targeted doxorubicin nanoparticles. PLoS One (2012) 0.86
Development of an ELISA-array for simultaneous detection of five encephalitis viruses. Virol J (2012) 0.86
Herpes simplex virus type 2 triggers reactivation of Kaposi's sarcoma-associated herpesvirus from latency and collaborates with HIV-1 Tat. PLoS One (2012) 0.86
Incidence and risk of high-grade stomatitis with mTOR inhibitors in cancer patients. Cancer Invest (2015) 0.85
Photoexcitation of tumor-targeted corroles induces singlet oxygen-mediated augmentation of cytotoxicity. J Control Release (2012) 0.84
Persistent hypocalcemia induced by zoledronic acid in a patient with androgen-independent prostate cancer and extensive bone metastases. Clin Genitourin Cancer (2007) 0.84
Brain microvascular endothelial cells mediate neuroprotective effects on ischemia/reperfusion neurons. J Ethnopharmacol (2010) 0.84
Exploration of the mechanism for LPFFD inhibiting the formation of beta-sheet conformation of A beta(1-42) in water. J Mol Model (2010) 0.84
Anti-vascular endothelial growth factor antibody bevacizumab reduced the risk of anemia associated with chemotherapy-A meta-analysis. Acta Oncol (2011) 0.83
The risk of nail changes with epidermal growth factor receptor inhibitors: a systematic review of the literature and meta-analysis. J Am Acad Dermatol (2011) 0.83
Risk of rash associated with lenalidomide in cancer patients: a systematic review of the literature and meta-analysis. Clin Lymphoma Myeloma Leuk (2013) 0.83
Inverse association between eczema and meningioma: a meta-analysis. Cancer Causes Control (2011) 0.82
Molecular dynamics simulation of melting and crystallization processes of polyethylene clusters confined in armchair single-walled carbon nanotubes. J Mol Model (2015) 0.82
The risk of rash associated with ipilimumab in patients with cancer: a systematic review of the literature and meta-analysis. J Am Acad Dermatol (2013) 0.81
The possible role of cranio-cervical trauma and abnormal CSF hydrodynamics in the genesis of multiple sclerosis. Physiol Chem Phys Med NMR (2011) 0.81
Risk of rash with the anti-HER2 dimerization antibody pertuzumab: a meta-analysis. Breast Cancer Res Treat (2012) 0.80
Phase II trial of bortezomib alone or in combination with irinotecan in patients with adenocarcinoma of the gastroesophageal junction or stomach. Invest New Drugs (2014) 0.79
MoGrr1, a novel F-box protein, is involved in conidiogenesis and cell wall integrity and is critical for the full virulence of Magnaporthe oryzae. Appl Microbiol Biotechnol (2015) 0.79
Eosinophilic pneumonia associated with bleomycin in a patient with mediastinal seminoma: a case report. J Med Case Rep (2010) 0.78
Replacement of the membrane proximal region of I-A(d) MHC class II molecule with I-E-derived sequences promotes production of an active and stable soluble heterodimer without altering peptide-binding specificity. J Immunol Methods (2005) 0.78
Phase I trial of intraperitoneal gemcitabine in the treatment of advanced malignancies primarily confined to the peritoneal cavity. Clin Cancer Res (2007) 0.78
A phosphoproteomic screen demonstrates differential dependence on HER3 for MAP kinase pathway activation by distinct PIK3CA mutations. Proteomics (2014) 0.78
Exploration of the binding of proton pump inhibitors to human P450 2C9 based on docking and molecular dynamics simulation. J Mol Model (2010) 0.78
Early biomarkers for post-stroke cognitive impairment. J Neurol (2012) 0.77
Exploration of the binding of benzimidazole-biphenyl derivatives to hemoglobin using docking and molecular dynamics simulation. Int J Biol Macromol (2010) 0.77
Function of CD147 in atherosclerosis and atherothrombosis. J Cardiovasc Transl Res (2015) 0.77
Esculentoside A suppresses Aβ(1-42)-induced neuroinflammation by down-regulating MAPKs pathways in vivo. Neurol Res (2015) 0.76
A highly active catalytic system for Suzuki-Miyaura cross-coupling reactions of aryl and heteroaryl chlorides in water. Org Biomol Chem (2012) 0.76
Molecular dynamic simulations reveal the mechanism of binding between xanthine inhibitors and DPP-4. J Mol Model (2014) 0.76
Pruritus to anticancer agents targeting the EGFR, BRAF, and CTLA-4. Dermatol Ther (2013) 0.76
Controversial role of bevacizumab in the development of venous thromboembolic events. J Clin Oncol (2011) 0.75